ArticleBlood cancer journal2026

Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab.

Febe Smits et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.